Bruton’s tyrosine kinase has emerged as a promising drug target for multiple diseases, particularly hematopoietic malignancies. As a result of intensive efforts, many inhibitors have been developed to target BTK. Among them, considerable progress has been made in covalent inhibitors. In this chapter, example compounds will be discussed to highlight our current understanding of the functional and structural features of BTK inhibitors.